Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 9/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 2/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200149 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19182810 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19183401 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19182811 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19200896 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20678754 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20678612 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20678603 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20678605 | 1.00 | GRM7 (0.62) | GRM7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20678619 | 0.90 | GRM7 (0.72) | GRM7CNR1PYGLMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | claimed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | claimed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | claimed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | GRM7 1/4885PSEN1 1092/4885PSEN2 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.